Working Paper

Pharmaceutical Prices: The Impact of the Launch Strategy

Authors

  • Yvonne-Beatrice Böhler
  • Christian Lamping
  • Philipp Wichardt
Publication Date

This paper reports the results from a statistical analysis of pharmaceutical price negotiations in Germany, where the pricing system was changed in 2011 in order to tie prices more to the benefits of the pharmaceuticals. A multiple linear regression of 187 pharmaceuticals which were assessed from 2011 to 2017 suggests that, despite the change, the manufacturers’ launch strategy (freely chosen first year price) still has a major impact on pricing while the impact of the additional benefit remains comparably small. Moreover, the data suggest that the assessment of the Federal Joint Committee - while not yet existing at the point - best explains the manufacturer’s launch strategy, indicating that manufacturers know more than they reveal.

Kiel Institute Expert

Info

JEL Classification
I10

Key Words

  • AMNOG
  • early benefit assessment
  • Pharmaceuticals

Related Topics